MET and neoplasm: Mechanistically, ADCs such as telisotuzumab vedotin and amivantamab exert effects following antibody binding via more targeted, direct delivery of a cytotoxic payload to the tumor cells, limiting any resistance mechanisms that may be related to intracellular signaling, such as MET amplification in EGFR TKI resistance (37).